Erectile dysfunction and heart failure: The role of phosphodiesterase type 5 inhibitors

International Journal of Impotence Research

Volumn 21, Issue 3, 2009, Pages 149-157

  Al Ameri, H ^a   Kloner, R A ^a,b  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Efficacy; Heart failure; Mechanism; Phosphodiesterase 5 inhibitor; Safety

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIGOXIN; NITRATE; NORADRENALIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; THIAZIDE DIURETIC AGENT; VARDENAFIL; VASODILATOR AGENT; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V;

AORTA STENOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLURRED VISION; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; EXERCISE; FLUID THERAPY; FLUSHING; GASTROESOPHAGEAL REFLUX; HEART DISEASE; HEART FAILURE; HEART INDEX; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; HYPOTENSION; INDUCED HYPOTENSION; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MYALGIA; PENIS ERECTION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEXUAL BEHAVIOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; DRUG ANTAGONISM; MALE;

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE INHIBITORS; RISK ASSESSMENT;

EID: 67649205171     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2009.11     Document Type: Review

References (54)

1. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-1813.
2. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-1404.
3. Katz SD, BalidemajK, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845-851.
4. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47: 214-220.
5. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007; 19:200-207.
6. Mazo E, Gamidov S, Iremashvili V. The effect of vardenafil on endothelial function of brachial and cavernous arteries. Int J Impot Res 2006; 18: 464-469.
7. Billups KL. Erectile dysfunction as an early sign of cardiovascular disease. Int J Impot Res 2005; 17: S19-S24.
8. Kloner RA. Erectile dysfunction as a predictor of cardiovascular disease. Int J Impot Res 2008; 20: 460-465.
9. Kloner R, Padma-Nathan H. Erectile dysfunction in patients with coronary artery disease. Int J Impot Res 2005;17: 209-215.
10. Kloner R. Erectile dysfunction and hypertension. Int JImpot Res 2007; 19: 296-302.
11. Rastogi S, Rodriguez JJ, Kapur V, Schwarz ER. Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem. Int J Impot Res 2005; 17: S25-S36.
12. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117:e25-146.
13. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
14. Jaarsma T, Dracup K, Walden J, Stevenson LW. Sexual function in patients with advanced heart failure. Heart Lung 1996; 25:262-270.
15. Herbert K, Lopez B, Castellano J, Palacio A, Tamari L, Arcemen LM. The prevalence of erectile dysfunction in heart failure patients by race and ethnicity. Int JImpot Res 2008; 20:507-511.
16. Schwarz ER, Kapur V, Bionat S, Rastogi S, Gupta R, Rosanio S. The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure. Int JImpot Res 2008; 20: 85-91.
17. Goldstein I. The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am JCardiol 2000; 86: 41F-45F.
18. Schwarz ER, Rastogi S, Kapur V, Sulemanjee N, Rodriguez JJ. Erectile dysfunction in heart failure patients. J Am Coll Cardiol 2006; 48: 1111-1119.
19. Grimm Jr RH, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8-14.
20. Gupta S, Salimpour P, Saenz de Tejada I, Daley J, Gholami S, Baller M et al. A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphate activity. J Urol 1998; 159: 1529-1536.
21. Muguruma H, Kawanishi Y, Sugiyama H, Kagawa J, Tanimoto S, Yamanaka M et al. Effect of aldosterone on isolated human penile corpus cavernosum tissue. BJU Int 2008; 102:500-503.
22. Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RHG. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007; 34:327-331.
23. Baumhäkel M, Schlimmer N, Böhm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int JImpot Res 2008; 20: 493-500.
24. Toblli JE, Stella I, Mazza ON, Ferder L, Inserra F. Different effect of losartan and amlodipine on penile structures in male spontaneously hypertensive rats. Am J Nephrol 2004; 24: 614-623.
25. Toblli JE, Cao G, Casas G, Mazza ON. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats. Am J Hypertens 2006; 19: 1226-1232.
26. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 313-321.
27. Mandras SA, Uber PA, Mehra MR. Sexual activity and chronic heart failure. Mayo Clin Proc 2007; 82: 1203-1210.
28. Cremers B, Kjellstrom B, Sudkamp M, Bohm M. Hemodynamic monitoring during sexual intercourse and physical exercise in a patient with chronic heart failure and pulmonary hypertension (letter). Am J Med 2002; 112: 428-430.
29. Katz SD, Parker JD, Glasser DB, Bank AJ, Sherman N, Wang H et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005; 95: 36-42.
30. Webster LJ, Michelakis ED, Davis T, Archer SL. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med 2004; 164: 514-520.
31. Freitas D, Athanazio R, Almeida D, Dantas N, Reis F. Sildenafil improves quality of life in men with heart failure and erectile dysfunction. Int J Impot Res 2006; 18:210-212.
32. Cheitlin MD, Hutter Jr. AM, Brindis RG, Ganz P, Kaul S, Russell RO et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33: 273-282.
33. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase- 5 inhibitors approved for the treatment oferectile dysfunction. Circulation 2004; 110: 3149-3155.
34. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42:1855-1860.
35. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106: 1097-1103.
36. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005; 96: 1436-1440.
37. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME et al. Sildenafil improves exercise hemody- namics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115: 59-66.
38. Al-Hesayen A, Floras JS, Parker JD. The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. Eur J Heart Fail 2006; 8: 864-868.
39. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008; 14: 189-197.
40. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long- term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136-2144.
41. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555-1562.
42. Katz SD. Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. CHF 2003; 9: 9-15.
43. Iyengar S, Haas GJ, Young JB. Acute heart failure. In: Topol EJ (ed). Textbook of Cardiovascular Medicine 3rd edn. Lippincott Williams & Wilkins: Philadelphia, 2007, pp 1352-1372.
44. Mason DT. Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure. Am J Med 1978; 65:106-125.
45. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C-12C.
46. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116: 238-248.
47. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 2009; 119: 408-416.
48. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans. Circulation 2005; 112: 2642-2649.
49. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11: 214-222.
50. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
51. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 44:1488-1496.
52. Aizawa K, Hanaoka T, Kasai H, Kogashi K, Kumazaki S, Koyama J et al. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res 2006; 29: 123-128.
53. Affuso F, Palmieri EA, Di CP, Guardasole V, Fazio S. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 2006; 108:429-431.
54. Singh TS, Kumar D, Basu S, Panja M, Mitra B. Tadalafil in the management of severe pulmonary artery hypertension. Indian Heart J2006; 58: 52-53.